Oncotarget
AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- New Hypothesis Links HPV E6 and SARS‑CoV‑2 Spike Proteins to Reduced p53 Activity
A new hypothesis article was published in Oncotarget (Volume 17) on January 3, 2026, titled “Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53.” - Evaluation of Cancer Reports Following COVID-19 Vaccination and Infection
A new review was published in Oncotarget (Volume 17) on January 3, 2026, titled “COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms.” - Colorectal Cancer Survival Predicted by AI Using Clinical and Molecular FeaturesA new research paper was published in Oncotarget (Volume 16) on December 15, 2025, titled “Machine learning-based survival prediction in colorectal cancer combining clinical and biological features.”
ABOUT DR. MIKHAIL (MISHA) BLAGOSKLONNY:
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time.
Dr. Blagosklonny was born into a family of scientists. His mother, Professor of Medicine Yanina V. Blagosklonnaya, specialized in endocrinology and was a talented teacher, mentoring several generations of medical students. His father, Professor Vladimir M. Dilman, was a brilliant gerontologist, endocrinologist and oncologist, known for being a very charismatic person. He was the first person to encourage Misha to think about nature, aging, and philosophy.
Misha was a theorist by nature. While in school, he was deeply interested in physics and dreamed of becoming a theoretical physicist. Eventually, he chose biology, driven to study aging and age-related diseases, including cancer. He started as an experimentalist, but over the years, he became a theoretical biologist. In a way, his dream came true.
Read the full tribute to Dr. Blagosklonny | @Blagosklonny
ABOUT ONCOTARGET.NET:
Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget, an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
CONTACT INFORMATION:
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.